Log in to save to my catalogue

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung c...

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung c...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2476769847

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

About this item

Full title

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

Publisher

London: Nature Publishing Group UK

Journal title

Oncogene, 2020-02, Vol.39 (9), p.1846-1859

Language

English

Formats

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

EGFR
-mutant non-small-cell lung cancer (NSCLC) patients inevitably develop drug resistance when treated with EGFR tyrosine kinase inhibitors (TKIs). Systematic genetic analysis is important to understand drug-resistant mechanisms; however, the clinical significance of co-occurring genetic alterations at baseline, co-acquired mutations at progre...

Alternative Titles

Full title

Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2476769847

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2476769847

Other Identifiers

ISSN

0950-9232

E-ISSN

1476-5594

DOI

10.1038/s41388-019-1104-z

How to access this item